Monday, December 1, 2025

El-Khoury & Zaatari: Pathologist, AI, and the Future. Plus lots of great citations.

›
I probably saw this post via someone at Linked-In, but I've mislaid how I heard about it.   Worth reading, a new open-access paper, whic...

Communications Expert Assesses Trump-Mamdani Conference, Line by Line

›
On YouTube, communications expert Chris Miller goes through the Trump-Mamdani Oval Office meeting and describes his view of how each politi...

LegislationWatch: Proposed: Bill for Alzheimer Blood Testing in Medicare, H.R. 6130

›
Legislation watch:  A bill is introduced which would cover preventive screening with blood tests for Alzheimer's disease.    The full le...

Humor: When Medicare Pays for a Covid Test / Nursing Home

›
From time to time I have work related to Medicare's 14-day-rule, which is difficult to explain even with graphics and charts. This looks...
Saturday, November 29, 2025

Noted: Luis Cano's Essay on "Invisible War in Digital Pathology"

›
 Luis Cano MD PhD is a Paris-based expert on digital pathology.  Find his Linked in here .  His article feed here .   His Substack articles,...

Not Bad for a Machine: Chat GPT Offers to Review CMS & AI for Me

›
For almost three years, I've had a $20 a month subscription to Chat GPT.  Like other AI's, the home page me offers me topics for the...

Remarkable Series of Articles on Digital Medicine from Flavio Angei (Linked In)

›
I've started noticing the rapid flow of articles highlighted every week by Flavio Angei at Linked-In. Find his home page here: https://w...

Goranatis et al. Weigh In on "Value & Valuation" of Genomics

›
First, updating some links on new reviews of MCED.   Then, we look at a new paper by Goriatis, Buchanan, et al in Nature Medicine on valuati...
Tuesday, November 25, 2025

CMS Issues "Request for Information" - Strategic Directions for Medicare Advantage

›
 CMS has issued its CY2027 proposed rule for Medicare Advantage.  It includes a "request for information" about future strategic d...

Big News: FDA to Down-Classify Many Companion Diagnostics as Class II (510k)

›
Last year, when FDA was sparring with stakeholders and courts over its LDT regulations, FDA promised to downclassify many types of diagnosti...